Valeant Pharmaceuticals International Inc up (U.S.)$0.02

Valeant Pharmaceuticals International Inc closed up Friday by (U.S.)$0.02 or 0.13% to (U.S.)$15.46. Although unchanged over the last five days, shares are down 84.79% for the last year to date. This security has underperformed the S&P 500 by 93.97% during the last year.

Key company metrics

Open(U.S.) $15.44

Previous close(U.S.) $15.44

High(U.S.) $15.89

Low(U.S.) $15.35

Bid / Ask-- / --

YTD % change-84.79%

Volume9,223,041

Average volume (10-day)13,191,186

Average volume (1-month)23,367,418

Average volume (3-month)22,067,792

52-week range(U.S.) $13.77 to (U.S.) $119.87

Beta-0.13

Trailing P/ENegative, not meaningful

P/E 1 year forward2.84×

Forward PEG0.23×

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) -$6.48

Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.

Key company metrics

Open(U.S.) $15.44

Previous close(U.S.) $15.44

High(U.S.) $15.89

Low(U.S.) $15.35

Bid / Ask-- / --

YTD % change-84.79%

Volume9,223,041

Average volume (10-day)13,191,186

Average volume (1-month)23,367,418

Average volume (3-month)22,067,792

52-week range(U.S.) $13.77 to (U.S.) $119.87

Beta-0.13

Trailing P/ENegative, not meaningful

P/E 1 year forward2.84×

Forward PEG0.23×

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) -$6.48

Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic

Continue reading

and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Profit

Net Profit (TTM)

-22.57%

Valeant Pharmaceuticals International Inc has a net profit margin of -22.57%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit. Company Books

Restrictions

All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.